Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Boeing Co (BA) vs Baxter International Inc (BAX) Price & Performance

Baxter International IncTrade

Price performance (Past 24H)

Key statistics

Boeing Co vs Baxter International Inc — how do they compare? Boeing Co trades at $233.15 (market cap $183.99B), while Baxter International Inc trades at $27.61 (market cap $14.36B). The key difference: Boeing Co is far larger — about 12.8× Baxter International Inc's market cap, and Baxter International Inc pays the higher dividend (0.14%). Which is the better fit depends on your goals.

BABAX
Market Cap
$183.99B$14.36B
Volume
7,591,579
Sector
IndustrialsHealth
52-Week High
$252.15$28.35
52-Week Low
$179.12$15.80
Enterprise Value
$209.87B$21.88B
Dividend Yield
0.03%0.14%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Boeing Co

Boeing (BA) trades at $234.42, up 0.96% on the day, with a bullish technical outlook supported by moving averages and strong analyst consensus. The company reported revenue of $89.46 billion in 2025, turning a net profit of $2.24 billion after years of losses, though margins remain thin. Recent news highlights a strategic deal with Archer Aviation, transferring three subsidiaries for a 19.75% stake, potentially enhancing Boeing's position in autonomous flight technology.

The outlook is cautiously optimistic, with a consensus price target of $284 offering ~21% upside, but risks include high debt, regulatory scrutiny from FAA inspections, and volatile cash flows. Investors should weigh the recovery in commercial aerospace against execution challenges and macroeconomic headwinds.

Baxter International Inc

Baxter International (BAX) trades at $27.55, up 2.0% today, showing strong momentum after recent earnings beats. The stock is approaching its 52-week high of $29.35, with technical indicators signaling bullish momentum. Fundamentally, the company reported Q2 2026 earnings of $0.56 per share, beating estimates, and raised full-year guidance, though profitability metrics remain negative with a -9.27% net income margin. Recent news highlights operational improvements and strong demand for IV solutions.

The outlook is cautiously optimistic as Baxter demonstrates turnaround progress with raised guidance and earnings beats. Investment opportunity lies in continued operational execution and margin recovery, but risks include persistent negative profitability, high debt levels, and competitive pressures in the medtech space. Wall Street sentiment is mixed with 42% buy ratings but a consensus price target below current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Boeing Co

The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The Company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.

Read more on BA

About Baxter International Inc

Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.

Read more on BAX